ClinicalTrials.gg
CompletedNCT04650854Updated Aug 20, 2026Results posted

A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis

A Phase 3 interventional study of Rozanolixizumab in Generalized Myasthenia Gravis, sponsored by UCB Biopharma SRL. Completed at 69 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing rozanolixizumab in Myasthenia Gravis — 2 open to participants now, 4 under way, 3 of them phase 3. rozanolixizumab · Myasthenia Gravis.

Enrollment
2nd of 10
165 · median 67
Started
2021
the only one that year
Phase 3
7 of 10
2 open now
Registered
4th of 10
by date
Lead sponsor
9 of 10
UCB Biopharma SRL

Among the 10 studies testing rozanolixizumab in Myasthenia Gravis, this one is the 2nd largest by enrollment, is the only one that started in 2021, is one of 7 in phase 3, and was the 4th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

2 of the 10 studies testing rozanolixizumab in Myasthenia Gravis are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About rozanolixizumab

rozanolixizumab: first FDA approval 2023 (RYSTIGGO), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing rozanolixizumab in Myasthenia Gravis, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability and efficacy of additional 6-week treatment cycles with rozanolixizumab in study participants with generalized myasthenia gravis (gMG).

03

Conditions studied

  • Generalized Myasthenia Gravis

Browse trials for

Keywords

  • UCB7665
  • generalized myasthenia gravis
  • rozanolixizumab
  • gMG
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participant must meet one of the following:

    1. completed MG0003 [NCT03971422]
    2. required rescue therapy during the Observation Period in MG0003 or
    3. completed at least 6 visits in MG0004 [NCT04124965]
  • Body weight ≥35 kg at Baseline (Day 1)
  • Study participants may be male or female

Exclusion criteria

Exclusion Criteria:

  • Study participant has a known to any components of the study medication or other anti-neonatal Fc receptor (FcRn) medications
  • Study participant with a known tuberculosis (TB) infection, at high risk of acquiring TB infection, or latent tuberculosis infection (LTBI), or current/history of nontuberculous mycobacterial infection (NTMBI)
  • Study participant met any mandatory withdrawal or mandatory study drug discontinuation criteria in MG0003, or MG0004, or permanently discontinued study drug in either study
  • Study participant intends to have a during the course of the study or within 8 weeks following the final dose of rozanolixizumab
  • Study participant with severe (defined as Grade 3 on the Myasthenia Gravis-Activities of Daily Living (MG-ADL) scale) weakness affecting oropharyngeal or respiratory muscles, or who has myasthenic crisis or impending crisis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
165 participants (actual)

Study arms

  • Experimental
    Rozanolixizumab dosage regimen 1

    Study participants randomized/assigned to dosage regimen 1 will receive assigned dosage of rozanolixizumab for the initial cycle. The dose regimen may be switched before the start of each subsequent treatment cycle based on investigator discretion.

    Drug: Rozanolixizumab

  • Experimental
    Rozanolixizumab dosage regimen 2

    Study participants randomized/assigned to dosage regimen 2 will receive assigned dosage of rozanolixizumab for the initial cycle. The dose regimen may be switched before the start of each subsequent treatment cycle based on investigator discretion.

    Drug: Rozanolixizumab

Interventions

  • Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.

    Also known as: UCB7665

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which did not necessarily had a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. TEAE was defined as any event that was not present prior to first dose of investigational medicinal product (IMP), or any unresolved event already present that worsened in intensity following treatment, up to 8 weeks after end of Treatment Period or after last dose of IMP in participants who discontinued study or IMP.

    Time frame: From Baseline (Day 1) to End of Study (up to 34 months)

  2. Percentage of Participants With TEAEs Leading to Withdrawal of Investigational Medicinal Product (IMP)

    An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. AEs leading to permanent withdrawal of study medication.

    Time frame: From Baseline (Day 1) to End of Study (up to 34 months)

Secondary outcomes

  1. Change From Baseline (Day 1) to Day 43 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Score Within One Treatment Cycle (Cycle 1, 2, and 3)

    The MG-ADL is an 8-item PRO instrument developed on basis of QMG. The MG-ADL targeted symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. The total MG-ADL score was obtained by summing responses to each individual item (8 items; Grades: 0, 1, 2, 3), where 0= no symptoms or impaired performance and 3= most severe symptoms or impaired performance. The total score ranges from 0 to 24, with higher score indicating more disability. A positive change in score indicates worsening and negative change indicates improvement. For analyses done by study cycle, Baseline values were last available values prior to or on the same date of first administration of IMP at each cycle (Baseline \[Day 1\]) value for that cycle.

    Time frame: From Baseline (Day 1) to Day 43 of each cycle (Cycles 1, 2, and 3)

  2. Change From Baseline (Day 1) to Day 43 in Quantitative Myasthenia Gravis (QMG) Score Within One Treatment Cycle (Cycle 1, 2, and 3)

    The QMG is a validated assessment and the scale tested 13 items, including ocular and facial involvement, swallowing, speech, limb strength, and forced vital capacity. The total QMG score was obtained by summing the responses to each individual item (13 items; Responses: None=0, Mild=1, Moderate=2, Severe=3) and the score ranges from 0 to 39, with lower scores indicating lower disease activity. A positive change in the score indicates worsening and a negative change indicates improvement. For the analyses done by study cycle, Baseline values were the last available values prior to or on the same date (and same time if time was collected for the individual assessment) of first administration of IMP at each cycle (ie, Baseline \[Day 1\]) value for that cycle.

    Time frame: From Baseline (Day 1) to Day 43 of each cycle (Cycles 1, 2, and 3)

  3. Change From Baseline (Day 1) to Day 43 in Myasthenia Gravis-Composite (MG-C) Score Within One Treatment Cycle (Cycle 1, 2, and 3)

    MG-C scale consists of 10 items which included ptosis (score range=0 to 3), double vision on lateral gaze left/right/both (score range=0 to 4), eye closure (score range=0 to 2), talking (score range=0 to 6), chewing (score range=0 to 6), swallowing (score range=0 to 6), breathing (score range=0 to 9), neck flexion or extension (score range=0 to 4), shoulder abduction (score range=0 to 5) and hip flexion (score range= 0 to 5), lower scores= lower disease activity. Total MG-C score obtained by summing responses to each individual item and score ranges from 0 - 50, (lower scores indicating lower disease activity). Positive change = worsening, and negative change = improvement. For analyses done by study cycle, Baseline values were last available values prior to or on the same date of first administration of IMP at each cycle (Baseline \[Day 1\]) value for that cycle.

    Time frame: From Baseline (Day 1) to Day 43 of each cycle (Cycles 1, 2, and 3)

  4. Change From Baseline (Day 1) to Day 43 in Myasthenia Gravis (MG) Symptoms Patient Reported Outcome (PRO) 'Muscle Weakness Fatigability' Score Within One Treatment Cycle (Cycle 1, 2, and 3)

    The MG symptoms PRO instrument consisted of 42 items across 5 scales: ocular symptoms (1-5); bulbar muscle weakness (6-15); respiratory muscle weakness (16-18); physical fatigue (19-33) and muscle weakness fatigability (34-42). Study participants had to choose response option that best described severity of ocular, bulbar, and respiratory symptoms over past 7 days using a 4-point Likert scale ("none" to "severe") and frequency of experiencing physical fatigue and muscle weakness fatigability over past 7 days using a 5-point Likert scale (1="none of the time" - 5= "all of the time"), for each item. Sum of each item score is linearly transformed to have all domain scores ranging from 0 to 100, higher scores indicates more severe symptoms. For analyses done by study cycle, Baseline values were last available values prior to or on the same date of first administration of IMP at each cycle (Baseline \[Day 1\]) value for that cycle.

    Time frame: From Baseline (Day 1) to Day 43 of each cycle (Cycles 1, 2, and 3)

  5. Change From Baseline (Day 1) to Day 43 in MG Symptoms PRO 'Physical Fatigue' Score Within One Treatment Cycle (Cycle 1, 2, and 3)

    The MG symptoms PRO instrument consisted of 42 items across 5 scales: ocular muscle weakness (1-5); bulbar muscle weakness (6-15); respiratory muscle weakness (16-18); physical fatigue (19-33) and muscle weakness fatigability (34-42). Study participants had to choose response option based on frequency of experiencing physical fatigue (19-33) over past 7 days using a 5-point Likert scale (1="none of time" - 5="all of time") for each item. Sum of each item score is linearly transformed to have all domain scores ranging from 0 to 100, higher scores indicated severe symptoms.

    Time frame: From Baseline (Day 1) to Day 43 of each cycle (Cycles 1, 2, and 3)

  6. Change From Baseline (Day 1) to Day 43 in MG Symptoms PRO 'Bulbar Muscle Weakness' Score Within One Treatment Cycle (Cycle 1, 2, and 3)

    The MG symptoms PRO instrument consisted of 42 items across 5 scales: ocular muscle weakness (1-5); bulbar muscle weakness (6-15); respiratory muscle weakness (16-18); physical fatigue (19-33) and muscle weakness fatigability (34-42). Bulbar symptoms are now recognised as bulbar muscle weakness. Study participants were asked to choose response option that best described severity of bulbar muscle weakness (6-15) symptoms over past 7 days using a 4-point Likert scale (1="none" to 4="severe") for each item. Sum of each item score is linearly transformed to have all domain scores ranging from 0 to 100, higher scores indicated severe symptoms.

    Time frame: From Baseline (Day 1) to Day 43 of each cycle (Cycles 1, 2, and 3)

  7. MG-ADL Responder Rate (>=2.0-point Improvement From Baseline [Day 1]) Within One Treatment Cycle (Cycle 1, 2, and 3 [Day 43])

    The MG-ADL is an 8-item PRO instrument developed on the basis of the Quantitative Myasthenia Gravis (QMG). The MG-ADL targeted symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. The total MG-ADL score was obtained by summing the responses to each individual item (8 items; Grades: 0, 1, 2, 3), where 0 represents no symptoms or impaired performance and 3 represents the most severe symptoms or impaired performance. The total score ranges from 0 to 24, with a higher score indicating more disability. A MG-ADL responder was defined as achieving at least 2.0-point improvement (decrease) in the MG-ADL score from Baseline.

    Time frame: Day 43 of Cycle 1, 2, and 3

  8. Time to MG-ADL Response (>=2.0-point Improvement From Baseline [Day 1]) Within One Treatment Cycle (Cycle 1, 2, and 3)

    Time to achieve MG-ADL response, defined as at least 2.0-point improvement from Baseline. Time to first MG-ADL response (in days) by study cycle was defined as date of first MG-ADL Response within study cycle - date of MG-ADL Baseline within study cycle + 1.

    Time frame: From Baseline (Day 1) to Day 43 of each cycle (Cycles 1, 2, and 3)

  9. Time Between Consecutive Treatment Cycles

    Time between consecutive treatment cycles: Study participants were assessed for MG worsening prior to repeated cycles. In case of symptom worsening (eg, an increase of 2.0 points on MG-ADL or 3.0 points on QMG scale) between assessments, resulted additional treatment, study participants undergone another 6-week treatment cycle followed by an Observation Period, based on Investigator's discretion. Time between treatment cycles was calculated as: date of first sc infusion in consecutive cycle - date of last sc infusion before new cycle + 1 (or date of censoring - date of last sc infusion before potential new cycle + 1).

    Time frame: From end of the 6-week treatment cycle (Day 43) to the next 6-week treatment cycle (Day 1), assessed up to 2.5 years

07

Results

Posted Apr 18, 2025

Participant flow

The study started to enroll participants in February 2021 and concluded in January 2024. Participant Flow refers to Full Analysis Set (FAS).

Participant flow — Overall Study
MilestoneEnrolled, But Not TreatedRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Started88077
Completed31516
Not completed56561
Withdrew: Adverse event11214
Withdrew: Lack of efficacy136
Withdrew: Lost to follow-up110
Withdrew: Withdrawal by subject2179
Withdrew: Last treatment per sponsor lplv timelines0126
Withdrew: Participant withdrawn after drug approved by fda001
Withdrew: Pi withdrew the patients from the study001
Withdrew: Withdraw per sponsor's directive010
Withdrew: Withdrawal due to prohibited treatment001
Withdrew: Use of rescue medication001
Withdrew: Last treatment per sponsor002
Withdrew: Rescue medication001
Withdrew: Participant want to start a family001
Withdrew: Withdraw based on sponsor decision001
Withdrew: Participant screened for mg0020023
Withdrew: Patient withdrawn due to inappropriate behavior010
Withdrew: Subject performed peot, not a completed subject010
Withdrew: Participant to be screened for mg0020 study045
Withdrew: End of study021
Withdrew: Wish to continue study imp in patient programme010
Withdrew: Participant received rescue medication010
Withdrew: Patient withdrawn; lack of imp shipments021
Withdrew: Last treatment per lplv, screened for mg0020022
Withdrew: Discontinued due to chronic heart failure001
Withdrew: Last treatment per sponsor lplv timelines- japan033
Withdrew: Enrollment cup001

Outcome measures

PrimaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which did not necessarily had a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. TEAE was defined as any event that was not present prior to first dose of investigational medicinal product (IMP), or any unresolved event already present that worsened in intensity following treatment, up to 8 weeks after end of Treatment Period or after last dose of IMP in participants who discontinued study or IMP.

Time frame:
From Baseline (Day 1) to End of Study (up to 34 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
percentage of participantsRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)78.494.1
PrimaryPercentage of Participants With TEAEs Leading to Withdrawal of Investigational Medicinal Product (IMP)

An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. AEs leading to permanent withdrawal of study medication.

Time frame:
From Baseline (Day 1) to End of Study (up to 34 months)
Reported as:
Number · percentage of participants
Percentage of Participants With TEAEs Leading to Withdrawal of Investigational Medicinal Product (IMP)
percentage of participantsRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Percentage of Participants With TEAEs Leading to Withdrawal of Investigational Medicinal Product (IMP)9.816.7
SecondaryChange From Baseline (Day 1) to Day 43 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Score Within One Treatment Cycle (Cycle 1, 2, and 3)

The MG-ADL is an 8-item PRO instrument developed on basis of QMG. The MG-ADL targeted symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. The total MG-ADL score was obtained by summing responses to each individual item (8 items; Grades: 0, 1, 2, 3), where 0= no symptoms or impaired performance and 3= most severe symptoms or impaired performance. The total score ranges from 0 to 24, with higher score indicating more disability. A positive change in score indicates worsening and negative change indicates improvement. For analyses done by study cycle, Baseline values were last available values prior to or on the same date of first administration of IMP at each cycle (Baseline \[Day 1\]) value for that cycle.

Time frame:
From Baseline (Day 1) to Day 43 of each cycle (Cycles 1, 2, and 3)
Reported as:
Mean · score on a scale
Change From Baseline (Day 1) to Day 43 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Score Within One Treatment Cycle (Cycle 1, 2, and 3)
score on a scaleRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Cycle 1: Treatment (Day 43)-3.7 ± 3.5-3.1 ± 2.9
Cycle 2: Treatment (Day 43)-2.9 ± 3.1-3.8 ± 3.9
Cycle 3: Treatment (Day 43)-3.3 ± 2.7-3.2 ± 3.3
SecondaryChange From Baseline (Day 1) to Day 43 in Quantitative Myasthenia Gravis (QMG) Score Within One Treatment Cycle (Cycle 1, 2, and 3)

The QMG is a validated assessment and the scale tested 13 items, including ocular and facial involvement, swallowing, speech, limb strength, and forced vital capacity. The total QMG score was obtained by summing the responses to each individual item (13 items; Responses: None=0, Mild=1, Moderate=2, Severe=3) and the score ranges from 0 to 39, with lower scores indicating lower disease activity. A positive change in the score indicates worsening and a negative change indicates improvement. For the analyses done by study cycle, Baseline values were the last available values prior to or on the same date (and same time if time was collected for the individual assessment) of first administration of IMP at each cycle (ie, Baseline \[Day 1\]) value for that cycle.

Time frame:
From Baseline (Day 1) to Day 43 of each cycle (Cycles 1, 2, and 3)
Reported as:
Mean · score on a scale
Change From Baseline (Day 1) to Day 43 in Quantitative Myasthenia Gravis (QMG) Score Within One Treatment Cycle (Cycle 1, 2, and 3)
score on a scaleRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Cycle 1: Treatment (Day 43)-4.5 ± 5.0-4.1 ± 4.2
Cycle 2: Treatment (Day 43)-3.9 ± 4.1-4.9 ± 5.5
Cycle 3: Treatment (Day 43)-5.1 ± 4.8-4.2 ± 4.4
SecondaryChange From Baseline (Day 1) to Day 43 in Myasthenia Gravis-Composite (MG-C) Score Within One Treatment Cycle (Cycle 1, 2, and 3)

MG-C scale consists of 10 items which included ptosis (score range=0 to 3), double vision on lateral gaze left/right/both (score range=0 to 4), eye closure (score range=0 to 2), talking (score range=0 to 6), chewing (score range=0 to 6), swallowing (score range=0 to 6), breathing (score range=0 to 9), neck flexion or extension (score range=0 to 4), shoulder abduction (score range=0 to 5) and hip flexion (score range= 0 to 5), lower scores= lower disease activity. Total MG-C score obtained by summing responses to each individual item and score ranges from 0 - 50, (lower scores indicating lower disease activity). Positive change = worsening, and negative change = improvement. For analyses done by study cycle, Baseline values were last available values prior to or on the same date of first administration of IMP at each cycle (Baseline \[Day 1\]) value for that cycle.

Time frame:
From Baseline (Day 1) to Day 43 of each cycle (Cycles 1, 2, and 3)
Reported as:
Mean · score on a scale
Change From Baseline (Day 1) to Day 43 in Myasthenia Gravis-Composite (MG-C) Score Within One Treatment Cycle (Cycle 1, 2, and 3)
score on a scaleRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Cycle 1: Treatment (Day 43)-7.6 ± 7.3-4.7 ± 5.7
Cycle 2: Treatment (Day 43)-5.7 ± 5.4-7.5 ± 7.0
Cycle 3: Treatment (Day 43)-6.8 ± 5.9-6.1 ± 7.2
SecondaryChange From Baseline (Day 1) to Day 43 in Myasthenia Gravis (MG) Symptoms Patient Reported Outcome (PRO) 'Muscle Weakness Fatigability' Score Within One Treatment Cycle (Cycle 1, 2, and 3)

The MG symptoms PRO instrument consisted of 42 items across 5 scales: ocular symptoms (1-5); bulbar muscle weakness (6-15); respiratory muscle weakness (16-18); physical fatigue (19-33) and muscle weakness fatigability (34-42). Study participants had to choose response option that best described severity of ocular, bulbar, and respiratory symptoms over past 7 days using a 4-point Likert scale ("none" to "severe") and frequency of experiencing physical fatigue and muscle weakness fatigability over past 7 days using a 5-point Likert scale (1="none of the time" - 5= "all of the time"), for each item. Sum of each item score is linearly transformed to have all domain scores ranging from 0 to 100, higher scores indicates more severe symptoms. For analyses done by study cycle, Baseline values were last available values prior to or on the same date of first administration of IMP at each cycle (Baseline \[Day 1\]) value for that cycle.

Time frame:
From Baseline (Day 1) to Day 43 of each cycle (Cycles 1, 2, and 3)
Reported as:
Mean · score on a scale
Change From Baseline (Day 1) to Day 43 in Myasthenia Gravis (MG) Symptoms Patient Reported Outcome (PRO) 'Muscle Weakness Fatigability' Score Within One Treatment Cycle (Cycle 1, 2, and 3)
score on a scaleRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Cycle 1: Treatment (Day 43)-17.6 ± 21.0-14.6 ± 17.2
Cycle 2: Treatment (Day 43)-13.2 ± 19.2-19.2 ± 21.6
Cycle 3: Treatment (Day 43)-12.8 ± 14.4-15.4 ± 17.7
SecondaryChange From Baseline (Day 1) to Day 43 in MG Symptoms PRO 'Physical Fatigue' Score Within One Treatment Cycle (Cycle 1, 2, and 3)

The MG symptoms PRO instrument consisted of 42 items across 5 scales: ocular muscle weakness (1-5); bulbar muscle weakness (6-15); respiratory muscle weakness (16-18); physical fatigue (19-33) and muscle weakness fatigability (34-42). Study participants had to choose response option based on frequency of experiencing physical fatigue (19-33) over past 7 days using a 5-point Likert scale (1="none of time" - 5="all of time") for each item. Sum of each item score is linearly transformed to have all domain scores ranging from 0 to 100, higher scores indicated severe symptoms.

Time frame:
From Baseline (Day 1) to Day 43 of each cycle (Cycles 1, 2, and 3)
Reported as:
Mean · score on a scale
Change From Baseline (Day 1) to Day 43 in MG Symptoms PRO 'Physical Fatigue' Score Within One Treatment Cycle (Cycle 1, 2, and 3)
score on a scaleRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Cycle 1: Treatment (Day 43)-16.5 ± 18.6-14.8 ± 18.5
Cycle 2: Treatment (Day 43)-13.6 ± 21.6-16.0 ± 18.2
Cycle 3: Treatment (Day 43)-15.3 ± 16.9-15.0 ± 18.4
SecondaryChange From Baseline (Day 1) to Day 43 in MG Symptoms PRO 'Bulbar Muscle Weakness' Score Within One Treatment Cycle (Cycle 1, 2, and 3)

The MG symptoms PRO instrument consisted of 42 items across 5 scales: ocular muscle weakness (1-5); bulbar muscle weakness (6-15); respiratory muscle weakness (16-18); physical fatigue (19-33) and muscle weakness fatigability (34-42). Bulbar symptoms are now recognised as bulbar muscle weakness. Study participants were asked to choose response option that best described severity of bulbar muscle weakness (6-15) symptoms over past 7 days using a 4-point Likert scale (1="none" to 4="severe") for each item. Sum of each item score is linearly transformed to have all domain scores ranging from 0 to 100, higher scores indicated severe symptoms.

Time frame:
From Baseline (Day 1) to Day 43 of each cycle (Cycles 1, 2, and 3)
Reported as:
Mean · score on a scale
Change From Baseline (Day 1) to Day 43 in MG Symptoms PRO 'Bulbar Muscle Weakness' Score Within One Treatment Cycle (Cycle 1, 2, and 3)
score on a scaleRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Cycle 1: Treatment (Day 43)-13.4 ± 19.8-11.6 ± 16.2
Cycle 2: Treatment (Day 43)-10.4 ± 16.2-15.5 ± 18.1
Cycle 3: Treatment (Day 43)-14.0 ± 16.8-13.0 ± 17.9
SecondaryMG-ADL Responder Rate (>=2.0-point Improvement From Baseline [Day 1]) Within One Treatment Cycle (Cycle 1, 2, and 3 [Day 43])

The MG-ADL is an 8-item PRO instrument developed on the basis of the Quantitative Myasthenia Gravis (QMG). The MG-ADL targeted symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. The total MG-ADL score was obtained by summing the responses to each individual item (8 items; Grades: 0, 1, 2, 3), where 0 represents no symptoms or impaired performance and 3 represents the most severe symptoms or impaired performance. The total score ranges from 0 to 24, with a higher score indicating more disability. A MG-ADL responder was defined as achieving at least 2.0-point improvement (decrease) in the MG-ADL score from Baseline.

Time frame:
Day 43 of Cycle 1, 2, and 3
Reported as:
Number · percentage of participants
MG-ADL Responder Rate (>=2.0-point Improvement From Baseline [Day 1]) Within One Treatment Cycle (Cycle 1, 2, and 3 [Day 43])
percentage of participantsRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Cycle 1: Treatment (Day 43)74.363.6
Cycle 2: Treatment (Day 43)62.567.7
Cycle 3: Treatment (Day 43)73.267.2
SecondaryTime to MG-ADL Response (>=2.0-point Improvement From Baseline [Day 1]) Within One Treatment Cycle (Cycle 1, 2, and 3)

Time to achieve MG-ADL response, defined as at least 2.0-point improvement from Baseline. Time to first MG-ADL response (in days) by study cycle was defined as date of first MG-ADL Response within study cycle - date of MG-ADL Baseline within study cycle + 1.

Time frame:
From Baseline (Day 1) to Day 43 of each cycle (Cycles 1, 2, and 3)
Reported as:
Median · days
Time to MG-ADL Response (>=2.0-point Improvement From Baseline [Day 1]) Within One Treatment Cycle (Cycle 1, 2, and 3)
daysRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Cycle 19.00 (8.00 to 15.00)22.00 (15.00 to 36.00)
Cycle 215.00 (10.00 to 17.00)15.00 (9.00 to 22.00)
Cycle 315.00 (9.00 to 15.00)15.00 (9.00 to 17.00)
SecondaryTime Between Consecutive Treatment Cycles

Time between consecutive treatment cycles: Study participants were assessed for MG worsening prior to repeated cycles. In case of symptom worsening (eg, an increase of 2.0 points on MG-ADL or 3.0 points on QMG scale) between assessments, resulted additional treatment, study participants undergone another 6-week treatment cycle followed by an Observation Period, based on Investigator's discretion. Time between treatment cycles was calculated as: date of first sc infusion in consecutive cycle - date of last sc infusion before new cycle + 1 (or date of censoring - date of last sc infusion before potential new cycle + 1).

Time frame:
From end of the 6-week treatment cycle (Day 43) to the next 6-week treatment cycle (Day 1), assessed up to 2.5 years
Reported as:
Median · days
Time Between Consecutive Treatment Cycles
daysRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Between Cycle 1 and Cycle 264.0 (9 to 883)51.0 (2 to 856)
Between Cycle 2 and Cycle 358.0 (1 to 631)50.0 (15 to 575)
Between Cycle 3 and Cycle 442.5 (27 to 399)43.0 (5 to 194)
Between Cycle 4 and Cycle 543.0 (9 to 181)43.0 (17 to 242)
Between Cycle 5 and Cycle 644.0 (22 to 192)43.0 (15 to 175)
Between Cycle 6 and Cycle 736.0 (8 to 348)43.0 (7 to 106)
Between Cycle 7 and Cycle 837.0 (22 to 87)37.0 (6 to 84)
Between Cycle 8 and Cycle 936.0 (8 to 120)36.0 (7.0 to 134)
Between Cycle 9 and Cycle 1029.0 (7 to 97)29.0 (8 to 72)
Between Cycle 10 and Cycle 1129.0 (8 to 64)29.0 (8 to 99)
Between Cycle 11 and Cycle 1223.0 (8 to 52)22.0 (7 to 37)
Between Cycle 12 and Cycle 1322.0 (6 to 36)22.0 (7 to 38)
Between Cycle 13 and Cycle 1429.0 (22 to 35)16.0 (8 to 65)
Between Cycle 14 and Cycle 1529.0 (29 to 64)9.0 (8 to 16)
Between Cycle 15 and Cycle 1623.0 (8 to 29)26.5 (9 to 44)
Between Cycle 16 and Cycle 1729.0 (29 to 29)—
Between Cycle 17 and Cycle 188.0 (8 to 8)—

Adverse events

Collected over Enrolled, but not treated: From Screening until End of Study (up to 34 months); Randomized participants: From Baseline (Day 1) until End of Study (up to 34 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enrolled, But Not Treated1/8 (12.5%)3/8 (37.5%)5/8 (62.5%)
Rozanolixizumab ~7 mg/kg1/102 (1%)16/102 (15.7%)67/102 (65.7%)
Rozanolixizumab ~10 mg/kg3/102 (2.9%)31/102 (30.4%)78/102 (76.5%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
EventEnrolled, But Not TreatedRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Cardiac failureCardiac disorders1/80/1021/102
Myocardial infarctionCardiac disorders1/80/1021/102
Myasthenia gravisNervous system disorders1/85/10211/102
Myasthenia gravis crisisNervous system disorders1/80/1024/102
Respiratory failureRespiratory, thoracic and mediastinal disorders1/80/1020/102
COVID-19Infections and infestations0/81/1022/102
Iron deficiency anaemiaBlood and lymphatic system disorders0/80/1021/102
Angina unstableCardiac disorders0/80/1021/102
Atrial fibrillationCardiac disorders0/80/1021/102
Adrenal disorderEndocrine disorders0/81/1020/102
Most frequent other events
Showing 10 of 34
Most frequent other events
EventEnrolled, But Not TreatedRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
HeadacheNervous system disorders0/836/10246/102
DiarrhoeaGastrointestinal disorders0/820/10228/102
COVID-19Infections and infestations1/815/10224/102
PyrexiaGeneral disorders0/89/10219/102
NauseaGastrointestinal disorders0/89/10218/102
Blood immunoglobulin G decreasedInvestigations0/86/10215/102
NasopharyngitisInfections and infestations1/810/10211/102
Urinary tract infectionInfections and infestations1/86/1022/102
DyspnoeaRespiratory, thoracic and mediastinal disorders1/83/1026/102
Hepatic painGeneral disorders1/80/1020/102

Baseline characteristics

Baseline characteristics refers to the Full Analysis set (FAS) which consisted of all enrolled study participants who were randomized in this study or in MG0004.

Age, Continuous
Age, Continuous(years)Enrolled, But Not TreatedRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kgTotal
Mean59.6 ± 17.652.5 ± 15.752.2 ± 17.052.7 ± 16.4
Age, Customized
Age, Customized(Participants)Enrolled, But Not TreatedRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kgTotal
18 to <65 years56157123
65 to <85 years2191940
>=85 years1012
Sex: Female, Male
Sex: Female, Male(Participants)Enrolled, But Not TreatedRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kgTotal
Female3454896
Male5352969
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Enrolled, But Not TreatedRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kgTotal
American Indian/Alaskan native0000
Asian08816
Black3104
Native Hawaiian or other Pacific Islander0011
White45454112
Other/mixed0000
Missing1171432
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Enrolled, But Not TreatedRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kgTotal
Hispanic or Latino42410
Not Hispanic or Latino36360126
Missing1151329
08

Study locations

69 sites
  • Mg0007 50092
    Orange, California 92868, United States
  • Mg0007 50099
    San Francisco, California 94117, United States
  • Mg0007 50122
    Miami, Florida 33136, United States
  • Mg0007 50120
    Miami, Florida 33144, United States
  • Mg0007 50073
    Tampa, Florida 33612, United States
  • Mg0007 50075
    Augusta, Georgia 30912-0004, United States
  • Mg0007 50323
    Honolulu, Hawaii 96817, United States
  • Mg0007 50114
    Indianapolis, Indiana 46202, United States
  • Mg0007 50121
    Lexington, Kentucky 40536-0284, United States
  • Mg0007 50077
    New York, New York 10021, United States
  • Mg0007 50090
    Winston-Salem, North Carolina 27157, United States
  • Mg0007 50096
    Philadelphia, Pennsylvania 19104, United States
  • Mg0007 50113
    Houston, Texas 77030, United States
  • Mg0007 50071
    Edmonton, Canada
  • Mg0007 50066
    Montreal, Canada
  • Mg0007 50124
    Montreal, Canada
  • Mg0007 50070
    Québec, Canada
  • Mg0007 50069
    Toronto, Canada
  • Mg0007 40125
    Ostrava - Poruba, Czechia
  • Mg0007 40124
    Prague, Czechia
  • Mg0007 40128
    Aalborg, Denmark
  • Mg0007 40127
    Aarhus, Denmark
  • Mg0007 40126
    Copenhagen, Denmark
  • Mg0007 40129
    Bordeaux, France
  • Mg0007 40360
    Limoges, France
  • Mg0007 40132
    Nice, France
  • Mg0007 40133
    Paris, France
  • Mg0007 40131
    Strasbourg, France
  • Mg0007 20160
    Tbilisi, Georgia
  • Mg0007 20161
    Tbilisi, Georgia
  • Mg0007 20163
    Tbilisi, Georgia
  • Mg0007 20164
    Tbilisi, Georgia
  • Mg0007 20165
    Tbilisi, Georgia
  • Mg0007 40134
    Essen, Germany
  • Mg0007 40140
    Göttingen, Germany
  • Mg0007 40139
    Jena, Germany
  • Mg0007 40078
    Leipzig, Germany
  • Mg0007 40177
    Münster, Germany
  • Mg0007 40283
    Bologna, Italy
  • Mg0007 40144
    Milan, Italy
  • Mg0007 40307
    Naples, Italy
  • Mg0007 40146
    Pavia, Italy
  • Mg0007 40148
    Roma, Italy
  • Mg0007 40150
    Roma, Italy
  • Mg0007 20035
    Bunkyō City, Japan
  • Mg0007 20068
    Chiba, Japan
  • Mg0007 20078
    Hanamaki-shi, Japan
  • Mg0007 20079
    Hiroshima, Japan
  • Mg0007 20075
    Kobe, Japan
  • Mg0007 20071
    Nagasaki, Japan
  • Mg0007 20077
    Sendai, Japan
  • Mg0007 20070
    Shinjuku-ku, Japan
  • Mg0007 20076
    Shinjuku-ku, Japan
  • Mg0007 20032
    Suita, Japan
  • Mg0007 40155
    Gdansk, Poland
  • Mg0007 40154
    Lodz, Poland
  • Mg0007 40151
    Lublin, Poland
  • Mg0007 40153
    Poznan, Poland
  • Mg0007 20169
    Novosibirsk, Russia
  • Mg0007 20001
    Saint Petersburg, Russia
  • Mg0007 20028
    Saint Petersburg, Russia
  • Mg0007 20055
    Saint Petersburg, Russia
  • Mg0007 40467
    Niš, Serbia
  • Mg0007 40160
    Barcelona, Spain
  • Mg0007 40157
    L'Hospitalet de Llobregat, Spain
  • Mg0007 40350
    Murcia, Spain
  • Mg0007 40308
    San Sebastián de los Reyes, Spain
  • Mg0007 20081
    Taipei, Taiwan
  • Mg0007 20086
    Taipei, Taiwan
09

References and documents

Publications

  • Bril V, Druzdz A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K, Vu T, Boehnlein M, Grimson F, Houston N, Kerbusch V, Pulido-Valdeolivas I, Tarancon T, Vissing J. Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase III MycarinG study and two open-label extensions. Ther Adv Neurol Disord. 2026 Jun 29;19:17562864261458532. doi: 10.1177/17562864261458532. eCollection 2026. PubMed 42388397 ↗
  • Bril V, Druzdz A, Grosskreutz J, Habib AA, Kaminski HJ, Mantegazza R, Sacconi S, Utsugisawa K, Vu T, Boehnlein M, Gayfieva M, Greve B, Woltering F, Vissing J; MG0004 study investigators. Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study. J Neurol. 2025 Mar 19;272(4):275. doi: 10.1007/s00415-025-12958-9. PubMed 40105996 ↗
  • Bril V, Druzdz A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K, Vissing J, Vu T, Boehnlein M, Bozorg A, Gayfieva M, Greve B, Woltering F, Kaminski HJ; MG0003 study team. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023 May;22(5):383-394. doi: 10.1016/S1474-4422(23)00077-7. PubMed 37059507 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Jan 2024, 35 months.

Results were first posted in Apr 2025, 1 year 2 months after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 35 months is above that.

Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2020
First posted
Dec 3, 2020
StartActual
Feb 3, 2021
Primary completionActual
Jan 25, 2024
CompletionActual
Jan 25, 2024
Results first posted
Apr 18, 2025
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04650854
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Dec 3, 2020
Start date
Feb 3, 2021
Primary completion
Jan 25, 2024
Completion
Jan 25, 2024
Results posted
Apr 18, 2025
Last update
Aug 20, 2026

Study contacts

UCB Cares
study director · 001 844 599 22733 (UCB)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rozanolixizumab

Start the discussion